[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20065502L - Farmasoytiske sammensetninger. - Google Patents

Farmasoytiske sammensetninger.

Info

Publication number
NO20065502L
NO20065502L NO20065502A NO20065502A NO20065502L NO 20065502 L NO20065502 L NO 20065502L NO 20065502 A NO20065502 A NO 20065502A NO 20065502 A NO20065502 A NO 20065502A NO 20065502 L NO20065502 L NO 20065502L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
relates
present
glycopyrrolate
antimuscarinic
Prior art date
Application number
NO20065502A
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065502(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20065502L publication Critical patent/NO20065502L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske preparater omfattende det antimuskarine middel glykopyrrolat, for eksempel saltet glykopyrroniumbromid. Spesielt angår foreliggende oppfinnelse tørrpulver-preparater som viser forbedret stabilitet over tid og metoder for å produsere disse.
NO20065502A 2004-04-30 2006-11-29 Farmasoytiske sammensetninger. NO20065502L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20065502L true NO20065502L (no) 2007-01-24

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065502A NO20065502L (no) 2004-04-30 2006-11-29 Farmasoytiske sammensetninger.

Country Status (27)

Country Link
US (1) US20080063719A1 (no)
EP (3) EP1755555B1 (no)
JP (2) JP5000483B2 (no)
KR (1) KR101287919B1 (no)
CN (3) CN107252423A (no)
AU (2) AU2005237266B2 (no)
BR (1) BRPI0510500B8 (no)
CA (1) CA2563760C (no)
CY (6) CY1113069T1 (no)
DK (2) DK2422766T3 (no)
ES (2) ES2388289T3 (no)
GB (1) GB0409703D0 (no)
HK (2) HK1095282A1 (no)
HU (4) HUE025463T2 (no)
IL (2) IL178651A (no)
LT (1) LTC2422766I2 (no)
LU (2) LU92176I2 (no)
MX (2) MXPA06012493A (no)
NO (1) NO20065502L (no)
NZ (1) NZ550479A (no)
PL (2) PL1755555T3 (no)
PT (2) PT1755555E (no)
RU (1) RU2396943C2 (no)
SG (3) SG152292A1 (no)
SI (2) SI1755555T1 (no)
WO (1) WO2005105043A2 (no)
ZA (1) ZA200609350B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
RU2482838C2 (ru) * 2007-12-13 2013-05-27 Новартис Аг Органические соединения
KR20100095587A (ko) * 2007-12-13 2010-08-31 노파르티스 아게 유기 화합물
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
PT2400950T (pt) 2009-02-26 2019-08-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(6-{2-[(2,6-diclorobenzil)oxi]ethoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
US20120101077A1 (en) * 2009-04-24 2012-04-26 Schering Corporation Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
WO2011121425A1 (en) * 2010-03-31 2011-10-06 Glenmark Pharmaceuticals Limited Pharmaceutical powder composition for inhalation
RU2585101C2 (ru) * 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
KR20130062268A (ko) * 2010-04-21 2013-06-12 키에시 파르마슈티시 엣스. 피. 에이. 정전하가 감소된 입자를 제공하는 방법
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
ES2845185T3 (es) 2010-08-31 2021-07-26 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US20140275517A1 (en) * 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
PL3191081T3 (pl) * 2014-09-09 2020-09-07 Vectura Limited Formulacja zawierająca glikopirolan, sposób i urządzenie
PE20170690A1 (es) 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products Randd Inc Formulacion de polvo seco
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
WO2017153701A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10603306B2 (en) 2016-03-08 2020-03-31 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
CA3037092C (en) 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
EP3595631A1 (en) * 2017-03-15 2020-01-22 Vectura Limited Method and formulation
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
PT3585382T (pt) 2017-12-11 2021-08-19 Mereo Biopharma 1 Ltd Utilização de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida no tratamento de exacerbações agudas da doença pulmonar obstrutiva crónica
US11234967B2 (en) 2017-12-11 2022-02-01 Mereo Biopharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
EP4452222A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
ATE382386T1 (de) * 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT2283818T (pt) 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
AU2002222115B2 (en) * 2000-11-30 2006-09-28 Vectura Limited Method of making particles for use in a pharmaceutical composition
SK286394B6 (sk) * 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
AU2003228907A1 (en) * 2002-05-07 2003-11-11 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用

Also Published As

Publication number Publication date
HK1167334A1 (en) 2012-11-30
ZA200609350B (en) 2008-04-30
AU2005237266B2 (en) 2010-11-11
ES2546982T3 (es) 2015-09-30
DK1755555T3 (da) 2012-08-20
EP2422766A2 (en) 2012-02-29
IL178651A (en) 2012-12-31
HUE025463T2 (en) 2016-02-29
IL223545A0 (en) 2013-02-03
CY2015059I1 (el) 2020-05-29
CA2563760A1 (en) 2005-11-10
LU92176I2 (fr) 2013-05-27
HUS1500073I1 (hu) 2016-02-29
SG10201605001SA (en) 2016-08-30
PL1755555T3 (pl) 2012-11-30
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
GB0409703D0 (en) 2004-06-02
ES2388289T3 (es) 2012-10-11
PT2422766E (pt) 2015-10-12
AU2005237266A1 (en) 2005-11-10
CY2013012I2 (el) 2015-08-05
BRPI0510500A (pt) 2007-10-30
NZ550479A (en) 2009-11-27
LU92176I9 (no) 2019-01-04
CY2014015I1 (el) 2015-12-09
SG186673A1 (en) 2013-01-30
RU2006142322A (ru) 2008-06-20
RU2396943C2 (ru) 2010-08-20
EP1755555A2 (en) 2007-02-28
SI1755555T1 (sl) 2012-10-30
BRPI0510500B1 (pt) 2019-04-24
CN1964700A (zh) 2007-05-16
JP2007535522A (ja) 2007-12-06
MX341426B (es) 2016-08-18
KR101287919B1 (ko) 2013-07-18
SG152292A1 (en) 2009-05-29
SI2422766T1 (sl) 2015-10-30
CY1116655T1 (el) 2017-03-15
PL2422766T3 (pl) 2015-11-30
LTC2422766I2 (lt) 2020-02-10
JP5000483B2 (ja) 2012-08-15
CY2014015I2 (el) 2015-12-09
JP5124718B2 (ja) 2013-01-23
WO2005105043A2 (en) 2005-11-10
CY1113069T1 (el) 2015-08-05
EP2422767A2 (en) 2012-02-29
CY2013012I1 (el) 2015-08-05
CN107252423A (zh) 2017-10-17
HK1095282A1 (en) 2007-05-04
KR20070033978A (ko) 2007-03-27
WO2005105043A3 (en) 2006-05-04
EP2422766A3 (en) 2012-04-25
AU2011200543A8 (en) 2011-03-31
AU2011200543A1 (en) 2011-03-03
DK2422766T3 (da) 2015-08-31
PT1755555E (pt) 2012-08-17
JP2012031209A (ja) 2012-02-16
HUS1500072I1 (hu) 2016-02-29
IL223545A (en) 2016-04-21
CA2563760C (en) 2013-07-02
LU92392I2 (fr) 2015-11-02
CN102008453A (zh) 2011-04-13
EP1755555B1 (en) 2012-05-23
US20080063719A1 (en) 2008-03-13
HUS1300006I1 (hu) 2016-07-28
MXPA06012493A (es) 2007-01-29
AU2011200543B2 (en) 2012-11-29
CY2015060I1 (el) 2020-05-29
BRPI0510500B8 (pt) 2021-05-25
EP2422767A3 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
NO20065502L (no) Farmasoytiske sammensetninger.
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20076046L (no) Bindemidler
ATE432067T1 (de) Embolie-teilchen
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
MY174493A (en) Binding agents
TW200519089A (en) Biaryl sulfonamides and methods for using same
TW200716622A (en) Substituted piperidines
ATE361922T1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
ZA200709691B (en) N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
DE602004010164D1 (de) Capsaicinderivate und deren produktion und verwendung
EA200801414A1 (ru) Кальцилитические соединения
NO20070391L (no) Jernsulfatbasert fosfatadsorbent
ATE524076T1 (de) Niedrig-glykämische mischungen
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
EP1952613A4 (en) MEDIATOR, SOURCE AND METHOD FOR THE COMMON USE OF CONTENTS
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
NO20055830L (no) Proglitazpnsalter, sa som pioglitazonsulfat og farmasoytiske sammensetnnger og fremgangsmater ved bruk av de samme
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application